AKT1 and breast carcinoma: AKT1-E17K mutation in breast cancer can isolate β-catenin to the cell membrane, which decreases ZEB1 transcription and leads to an increase in E-cadherin expression and the reversal of epithelial-mesenchymal transformation, thus inhibiting tumor migration and invasion (John et al., 2022).